Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Gea-Banacloche Website

Juan C. Gea-Banacloche, M.D.

Selected Publications
1)  Couriel D, Carpenter PA, Pavletic S, Vogelsang GB, Martin PJ, Lee SJ, Flowers ME, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S, Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K, Moravec CK, Abramovitz L, Liebermann J, Berger A, Gerber L, Schubert M, Filipovich AH, Weisdorf D, Schubert MM, Shulman H, Schultz K, Mittelman B.
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.
Biol. Blood Marrow Transplant. 12: 375-96, 2006. [Journal]
2)  Gea-Banacloche JC.
Antibacterial prophylaxis reduced the incidence of fever in patients receiving chemotherapy for solid tumors or lymphoma.
ACP J. Club. 144: 42, 2006. [Journal]
3)  Muraro PA, Nikolov NP, Butman JA, Abati A, Gea-Banacloche J, Gress R, Lipsky P, Illei G, Pavletic S.
Granulocytic invasion of the central nervous system after hematopoietic.
Haematologica. 91: ECR21, 2006. [Journal]
4)  Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA.
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
J. Clin. Oncol. 23: 2346-57, 2005. [Journal]
5)  Sportès C, McCarthy NJ, Hakim F, Steinberg SM, Liewehr DJ, Weng D, Kummar S, Gea-Banacloche J, Chow CK, Dean RM, Castro KM, Marchigiani D, Bishop MR, Fowler DH, Gress RE.
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients.
Biol. Blood Marrow Transplant. 11: 472-83, 2005. [Journal]
6)  Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S, Gress R.
Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.
J. Clin. Oncol. 22: 3886-92, 2004. [Journal]
7)  Fowler DH, Foley J, Whit-Shan Hou J, Odom J, Castro K, Steinberg SM, Gea-Banacloche J, Kasten-Sportes C, Gress RE, Bishop MR.
Clinical.
Clin Gastroenterol Hepatol. 2: 237-45, 2004. [Journal]
8)  Gea-Banacloche JC, Opal SM, Jorgensen J, Carcillo JA, Sepkowitz KA, Cordonnier C.
Sepsis associated with immunosuppressive medications: an evidence-based review.
Crit. Care Med. 32: S578-90, 2004. [Journal]
9)  Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM.
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Crit. Care Med. 32: 858-73, 2004. [Journal]
10)  Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent J, Levy MM.
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Intensive Care Med. 30: 536-55, 2004. Full Text Article. [Journal]
11)  Bishop MR, Steinberg SM, Gress RE, Hardy NM, Marchigiani D, Kasten-Sportes C, Dean R, Pavletic SZ, Gea-Banacloche J, Castro K, Hakim F, Krumlauf M, Read EJ, Carter C, Leitman SF, Fowler DH.
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation.
Br. J. Haematol. 126: 837-43, 2004. [Journal]
12)  Gea-Banacloche J, Johnson RT, Bagic A, Butman JA, Murray PR, Agrawal AG.
West Nile virus: pathogenesis and therapeutic options.
Ann. Intern. Med. 140: 545-53, 2004. [Journal]
13)  Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ.
Clinical pharmacology of antifungal compounds.
Infect. Dis. Clin. North Am. 17: 159-91, ix, 2003. [Journal]
14)  Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH.
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Biol. Blood Marrow Transplant. 9: 162-9, 2003. [Journal]
15)  Haley M, Retter AS, Fowler D, Gea-Banacloche J, O'Grady NP.
The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis.
Clin. Infect. Dis. 37: e88-90, 2003. [Journal]
16)  Fowler D, Hou J, Foley J, Hakim F, Odom J, Castro K, Carter C, Read E, Gea-Banacloche J, Kasten-Sportes C, Kwak L, Wilson W, Levine B, June C, Gress R, Bishop M.
Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant.
Cytotherapy. 4: 429-30, 2002. [Journal]
17)  Sereti I, Gea-Banacloche J, Kan MY, Hallahan CW, Lane HC.
Interleukin 2 leads to dose-dependent expression of the alpha chain of the IL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation.
Clin. Immunol. 97: 266-76, 2000. [Journal]
18)  Gea-Banacloche JC, Martino L, Mican JM, Hallahan CW, Baseler M, Stevens R, Lambert L, Polis M, Lane HC, Connors M.
Longitudinal changes in CD4+ T cell antigen receptor diversity and naive/memory cell phenotype during 9 to 26 months of antiretroviral therapy of HIV-infected patients.
AIDS Res. Hum. Retroviruses. 16: 1877-86, 2000. [Journal]
19)  Gea-Banacloche JC, Migueles SA, Martino L, Shupert WL, McNeil AC, Sabbaghian MS, Ehler L, Prussin C, Stevens R, Lambert L, Altman J, Hallahan CW, de Quiros JC, Connors M.
Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors.
J. Immunol. 165: 1082-92, 2000. [Journal]
20)  de Quiros JC, Shupert WL, McNeil AC, Gea-Banacloche JC, Flanigan M, Savage A, Martino L, Weiskopf EE, Imamichi H, Zhang YM, Adelsburger J, Stevens R, Murphy PM, Zimmerman PA, Hallahan CW, Davey RT, Connors M.
Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen.
J. Virol. 74: 2023-8, 2000. [Journal]

This page was last updated on 7/28/2006.